Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes

par Navada, Shyamala C., Silverman, Lewis R.
Publié dans Ther Adv Hematol (2016)

Clinical development of demethylating agents in hematology

par Navada, Shyamala C., Steinmann, Juliane, Lübbert, Michael, Silverman, Lewis R.
Publié 2014

JAK/STAT Pathways in Cytokine Signaling and Myeloproliferative Disorders: Approaches for Targeted Therapies

par Jatiani, Shashidhar S., Baker, Stacey J., Silverman, Lewis R., Reddy, E. Premkumar
Publié 2010

Azacitidine in Lower‐Risk Myelodysplastic Syndromes: A Meta‐Analysis of Data from Prospective Studies

par Komrokji, Rami, Swern, Arlene S., Grinblatt, David, Lyons, Roger M., Tobiasson, Magnus, Silverman, Lewis R., Sayar, Hamid, Vij, Ravi, Fliss, Albert, Tu, Nora, Sugrue, Mary M.
Publié dans Oncologist (2017)

Continued Azacitidine Therapy Beyond Time of First Response Improves Quality of Response in Patients With Higher-Risk Myelodysplastic Syndromes

par Silverman, Lewis R., Fenaux, Pierre, Mufti, Ghulam J., Santini, Valeria, Hellström-Lindberg, Eva, Gattermann, Norbert, Sanz, Guillermo, List, Alan F., Gore, Steven D., Seymour, John F.
Publié 2011

Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine

par Santini, Valeria, Fenaux, Pierre, Mufti, Ghulam J., Hellström-Lindberg, Eva, Silverman, Lewis R., List, Alan, Gore, Steven D., Seymour, John F., Backstrom, Jay, Beach, Charles L.
Publié 2010

Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best suppor...

par Garcia-Manero, Guillermo, Almeida, Antonio, Giagounidis, Aristoteles, Platzbecker, Uwe, Garcia, Regina, Voso, Maria Teresa, Larsen, Stephen R., Valcarcel, David, Silverman, Lewis R., Skikne, Barry, Santini, Valeria
Publié dans BMC Hematol (2016)

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care...

par Gore, Steven D., Fenaux, Pierre, Santini, Valeria, Bennett, John M., Silverman, Lewis R., Seymour, John F., Hellström-Lindberg, Eva, Swern, Arlene S., Beach, Charles. L., List, Alan. F.
Publié 2013

Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial

par Mesa, Ruben A., Silver, Richard T., Verstovsek, Srdan, Mascarenhas, John, Kessler, Craig M., Rondelli, Damiano, Goldberg, Judy D., Marchioli, Roberto, Demakos, Erin P., Silverman, Lewis R., Hoffman, Ronald
Publié 2013

Treatment of Myelodysplastic Syndrome with Two Schedules and Doses of Oral Topotecan: A Randomized Phase II Trial by the Cancer and Leukemia Group B (CALGB 19803)

par Grinblatt, David L., Yu, Daohai, Hars, Vera, Vardiman, James W., Powell, Bayard L., Nattam, Sreenivasa, Silverman, Lewis R., de Castro, Carlos, Stone, Richard M., Bloomfield, Clara D., Larson, Richard A.
Publié 2009

Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes

par Seymour, John F., Fenaux, Pierre, Silverman, Lewis R., Mufti, Ghulam J., Hellström-Lindberg, Eva, Santini, Valeria, List, Alan F., Gore, Steven D., Backstrom, Jay, McKenzie, David, Beach, C.L.
Publié 2010

Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leuke...

par Medeiros, Bruno C., McCaul, Kelly, Kambhampati, Suman, Pollyea, Daniel A., Kumar, Rajat, Silverman, Lewis R., Kew, Andrea, Saini, Lalit, Beach, CL, Vij, Ravi, Wang, Xiwei, Zhong, Jim, Gale, Robert Peter
Publié dans Haematologica (2018)

Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best...

par Nazha, Aziz, Sekeres, Mikkael A., Komrokji, Rami, Steensma, David P., Kantarjian, Hagop, Roboz, Gail, Fenaux, Pierre, Prebet, Thomas, Azarnia, Nozar, Zbyszewski, Patrick S., Fruchtman, Steven M., Santini, Valeria, Silverman, Lewis R., Platzbecker, Uwe, Garcia-Manero, Guillermo
Publié dans Blood Cancer J (2017)

Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies

par Feld, Jonathan, Tremblay, Douglas, Dougherty, Mikaela, Czaplinska, Tina, Sanchez, Gillian, Brady, Claudia, Kremyanskaya, Marina, Bar-Natan, Michal, Keyzner, Alla, Marcellino, Bridget K., Gabrilove, Janice, Navada, Shyamala C., Silverman, Lewis R., El Jamal, Siraj M., Mascarenhas, John, Shih, Alan H.
Publié dans Hemasphere (2021)

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

par Fenaux, Pierre, Mufti, Ghulam J, Hellstrom-Lindberg, Eva, Santini, Valeria, Finelli, Carlo, Giagounidis, Aristoteles, Schoch, Robert, Gattermann, Norbert, Sanz, Guillermo, List, Alan, Gore, Steven D, Seymour, John F, Bennett, John M, Byrd, John, Backstrom, Jay, Zimmerman, Linda, McKenzie, David, Beach, C L, Silverman, Lewis R
Publié 2009

Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results

par Heuser, Michael, Palmisiano, Neil, Mantzaris, Ioannis, Mims, Alice, DiNardo, Courtney, Silverman, Lewis R., Wang, Eunice S., Fiedler, Walter, Baldus, Claudia, Schwind, Sebastian, Pardee, Timothy, Perl, Alexander E., Cai, Charles, Kaulfuss, Stefan, Lagkadinou, Eleni, Rentzsch, Christine, Wagner, Markus, Wilkinson, Gary, Wu, Bingyan, Jeffers, Michael, Genvresse, Isabelle, Krämer, Alwin
Publié dans Leukemia (2020)

Phase I dose escalation study of lestaurtinib in patients with myelofibrosis

par Hexner, Elizabeth O, Mascarenhas J, John, Prchal, Josef, Roboz, Gail J, Baer, Maria R, Ritchie, Ellen K, Leibowitz, David, Demakos, Erin P, Miller, Crystal, Siuty, James, Kleczko, Jill, Price, Leah, Jeschke, Grace, Weinberg, Rona, Basu T, Titiksha, Pahl, Heike L, Orazi, Attilio, Najfeld, Vesna, Marchioli, Roberto, Goldberg, Judith D, Silverman, Lewis R, Hoffman, Ronald
Publié dans Leuk Lymphoma (2015)

MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis

par Rondelli, Damiano, Goldberg, Judith D., Isola, Luis, Price, Leah S., Shore, Tsiporah B., Boyer, Michael, Bacigalupo, Andrea, Rambaldi, Alessandro, Scarano, Marco, Klisovic, Rebecca B., Gupta, Vikas, Andreasson, Bjorn, Mascarenhas, John, Wetzler, Meir, Vannucchi, Alessandro M., Prchal, Josef T., Najfeld, Vesna, Orazi, Attilio, Weinberg, Rona S., Miller, Crystal, Barosi, Giovanni, Silverman, Lewis R., Prosperini, Giuseppe, Marchioli, Roberto, Hoffman, Ronald
Publié 2014

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies

par Fandy, Tamer E., Herman, James G., Kerns, Patrick, Jiemjit, Anchalee, Sugar, Elizabeth A., Choi, Si-Ho, Yang, Allen S., Aucott, Timothy, Dauses, Tianna, Odchimar-Reissig, Rosalie, Licht, Jonathan, McConnell, Melanie J., Nasrallah, Chris, Kim, Marianne K. H., Zhang, Weijia, Sun, Yezou, Murgo, Anthony, Espinoza-Delgado, Igor, Oteiza, Katharine, Owoeye, Ibitayo, Silverman, Lewis R., Gore, Steven D., Carraway, Hetty E.
Publié 2009

Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes

par Garcia-Manero, Guillermo, Santini, Valeria, Almeida, Antonio, Platzbecker, Uwe, Jonasova, Anna, Silverman, Lewis R., Falantes, Jose, Reda, Gianluigi, Buccisano, Francesco, Fenaux, Pierre, Buckstein, Rena, Diez Campelo, Maria, Larsen, Stephen, Valcarcel, David, Vyas, Paresh, Giai, Valentina, Olíva, Esther Natalie, Shortt, Jake, Niederwieser, Dietger, Mittelman, Moshe, Fianchi, Luana, La Torre, Ignazia, Zhong, Jianhua, Laille, Eric, Lopes de Menezes, Daniel, Skikne, Barry, Beach, C. L., Giagounidis, Aristoteles
Publié dans J Clin Oncol (2021)